Remdesivir, a widely employed antiviral nucleotide prodrug against COVID-19 (80), appears to antagonize acute kidney injury (AKI) by inhibiting NLRP3 inflammasome activation via the repression of NFkB and MAPK pathways in LPS-activated macrophages (81). The gene discussed is NLRP3; the disease is acute kidney injury.